Get started
Author

Sofie Wilgenhof

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
2019 · Leonie Voorwerk, Maarten Slagter, et al. · Nature Medicine · 906
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
2022 · Maartje W. Rohaan, Troels H. Borch, et al. · New England Journal of Medicine · 569
PDF
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
2024 · Christian U. Blank, Minke W. Lucas, et al. · New England Journal of Medicine · 543
Adoptive cellular therapies: the current landscape
2018 · Maartje W. Rohaan, Sofie Wilgenhof, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 398
PDF
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
2021 · Giuseppe Curigliano, Hans Gelderblom, et al. · Clinical Cancer Research · 359
PDF
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
2016 · Sofie Wilgenhof, Jurgen Corthals, et al. · Journal of Clinical Oncology · 313
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
2013 · S. Wilgenhof, A.M.T. Van Nuffel, et al. · Annals of Oncology · 203
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient
2011 · S. Wilgenhof, B. Neyns · Annals of Oncology · 175
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
2020 · Brenda De Keersmaecker, Sofie Claerhout, et al. · Journal for ImmunoTherapy of Cancer · 165
PDF
Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
2011 · Sofie Wilgenhof, An M.T. Van Nuffel, et al. · Journal of Immunotherapy · 159
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
2016 · Max Schreuer, Geert Meersseman, et al. · Journal of Translational Medicine · 143
PDF
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
2012 · Amélie Clémentine Seghers, Sofie Wilgenhof, et al. · Melanoma Research · 128
Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma Patients
2012 · An MT Van Nuffel, Daphné Benteyn, et al. · Molecular Therapy · 97
PDF
Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
2013 · Daphné Benteyn, An M. T. Van Nuffel, et al. · BioMed Research International · 89
PDF
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
2014 · Sandra Van Lint, Sofie Wilgenhof, et al. · Cancer Immunology Immunotherapy · 87
PDF
Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
2013 · Sofie Wilgenhof, Stephanie Du Four, et al. · Journal of Immunotherapy · 84
Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
2012 · Sofie Wilgenhof, Veerle Morlion, et al. · PubMed · 83
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
2014 · Sofie Wilgenhof, Jurgen Corthals, et al. · Cancer Immunology Immunotherapy · 76
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient
2011 · An M. T. Van Nuffel, Daphné Benteyn, et al. · Cancer Immunology Immunotherapy · 64
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies
2012 · Stephanie Du Four, Sofie Wilgenhof, et al. · European Journal of Cancer · 53
PDF
Overcoming HLA restriction in clinical trials
2012 · An M.T. Van Nuffel, Sofie Wilgenhof, et al. · OncoImmunology · 52
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR
2021 · Stéphanie A. Blankenstein, Maartje W. Rohaan, et al. · Annals of Surgery · 47
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
2022 · M.W. Rohaan, R. Gomez-Eerland, et al. · Immuno-Oncology Technology · 46
PDF
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
2015 · Yanina J. Jansen, Peter Janssens, et al. · Melanoma Research · 46
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
2025 · Jessica S. W. Borgers, Divya Lenkala, et al. · Nature Medicine · 45
PDF
Works count: 186
Citation count: 5,831
H-index: 32
I10-index: 63
Year
Topic
Type